(Date:5/16/2008)... Workers, WASHINGTON, May 16 /PRNewswire-USNewswi...cal technicians in the Greater Portland, Oregon an...irst-ever contract as,Teamsters., "The Teamsters ...a,strong contract that gives them job protection a...eral President Jim Hoffa., The workers, both full...
(Date:5/16/2008)... multicenter Phase III clinical trial has found th...AD001) significantly delays cancer progression in ...se had worsened on other treatments. The study wa... at Memorial Sloan-Kettering Cancer Center (MSKCC)...nnual meeting of the American Society for Clinical...
(Date:5/16/2008)...imary care medicine is in a precipitous decline, D...College of Physicians (ACP), today joined with le...o issue a call for comprehensive reforms to attrac... primary care physicians. , During a panel disc...e U.S., Dr. Dale and other panelists spoke about t...
(Date:5/16/2008)...ewswire-USNewswire/- "Huh, what did you,say?" is a...ularly our,children. More than 30 million American...aring loss and the numbers are growing at a dramat...dren have some form of hearing,loss. An effort to ...roblem,is what led Kathlyn Maguire, who has profou...
Breaking Medicine News(10 mins):Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3...may be the cause of migraines and severe headaches...dy mass //index on frequency, and severity of head...adaches are more common in obese people than those...ers had taken the physical history of the particip...
...ts have found out that increased calcium intake by...may increase the risk of Parkinson’s disease. Park...m. Some of its symptoms are muscle tremors, muscle...ty, stooped posture, slow voluntary movements, and...
...ug AVP-923 is all set to provide relief to people ...clerosis, said the researchers from University of ...s is a chronic neurological disease of the central...he brain and spinal cord and medication till date ...
...was undertaken to find out how to elevate the func...rom arthritis // by the researchers of Feinberg Sc...e study of age 65 yrs and old with arthritis. Func...y to do tasks pertaining to daily living and speci...
Other Medicine News:(Date:5/15/2008)...acy Clinical Data from Prostate, Colorectal and Ov...Company to Hold Investor Event on Sun., June 1 wit..., May 15 /- Poniard,Pharmac...al company focused,on oncology, today announced th...al trials of picoplatin, in various tumor types an...
(Date:5/15/2008)...ctions demonstrated in Blacks, Hispanics/Latinos, ...dividuals, PARSIPPANY, N.J., May 15 /PRNewswire/ ... presented at the American Society of,Hypertension...08) in New,Orleans demonstrated that the powerful ...an medoxomil) safely and effectively helped,patien...
(Date:5/15/2008).../- CenterWatch, a publishing and,info...h about clinical,trials, finds that investigative ...ic data capture) systems. More than 75% of respond... they had been trained on three or more,EDC system...ctiveness of,their EDC training had improved., St...
(Date:5/15/2008)...ected soon after CEA Trial data reports in third q...RANCISCO, May 15 /- VIA Pha...gy company focused on the development of,compounds...unced today that,it has completed patient enrollme... ACS study is one of three Phase 2 trials investig...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 1Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 2A maternal link to Alzheimers disease 5633 1A maternal link to Alzheimers disease 5633 2A maternal link to Alzheimers disease 5633 3Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 1Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 2Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 3Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 1Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 2Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 3...SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX...dministration (FDA) has,approved the Company,s Inv...inical development of MyocondaR to treat patients ...vium spp,paratuberculosis (MAP). , ,The Company un...,first therapy to be submitted to the FDA for this...
... ROCKVILLE, Md., April 18, 2007--Due to water dama...en forced to change the,location for the upcoming ...l 24, 2007 to discuss new drug application for,mar... to be held at,the FDA, Center for Drug Evaluation...Room, 5630 Fishers Lane, in Rockville, MD, the,mee...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: